[The HIV protease inhibitor-induced insulin resistance syndrome].
BACKGROUND
HIV protease inhibitors improve the morbidity and mortality of HIV infection, however, this therapy also initiates insulin resistance that is associated with an increasing development of disturbances in glucose and lipid metabolism. Similar to the common insulin resistance syndrome, treated patients also suffer from an increased cardiovascular risk.


METHODS
Studies based on animal or cell models suggest that HIV protease inhibitors induce short-term effects on GLUT4 glucose transport and longterm effects on insulin signal transduction.


CONCLUSIONS
Therapy with HIV protease inhibitors should include regular monitoring of metabolic alterations and cardiovascular damage. Particularly patients with genetic or traditional risk factors for type 2 diabetes should be monitored frequently.
Medizinische Klinik I, Universitätsklinikum Schleswig-Holstein, Campus Lübeck. morten.schuett@web.de
Morten
M
Schütt
Markus
M
Meier
Harald H
HH
Klein
D002318:Cardiovascular Diseases / Q000139:chemically induced / Q000503:physiopathology; D051275:Glucose Transporter Type 4; D015658:HIV Infections / Q000188:drug therapy* / Q000503:physiopathology; D017320:HIV Protease Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D024821:Metabolic Syndrome / Q000139:chemically induced* / Q000503:physiopathology; D009004:Monosaccharide Transport Proteins / Q000187:drug effects* / Q000502:physiology; D009124:Muscle Proteins; D012307:Risk Factors; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology
D051275:Glucose Transporter Type 4; D017320:HIV Protease Inhibitors; D009004:Monosaccharide Transport Proteins; D009124:Muscle Proteins; C495692:SLC2A4 protein, human